Showing results (1-10 of 16) with videos related to
Sort By:
Pageof 2
Metabolism: Clinical and Experimental|August 31, 2004
In vivo regulation of plasma free fatty acids in insulin resistanceS Mook, C j m Halkes Cj, S Bilecen, et al.Metabolism: Clinical and Experimental|August 5, 2003
Fasting and daylong triglycerides in obesity with and without type 2 diabetesJ P H van Wijk, C J M Halkes, D W Erkelens, et al.The Netherlands Journal of Medicine|July 28, 2007
Extreme leucocytosis: not always leukaemiaC J M Halkes, H M Dijstelbloem, S J Eelkman Rooda, et al.Journal of Internal Medicine|December 23, 2003
Diurnal triglyceridaemia and insulin resistance in mildly obese subjects with normal fasting plasma lipidsC J M Halkes, J P H Van Wijk, J Ribalta, et al.Netherlands Heart Journal : Monthly Journal of the Netherlands Society of Cardiology and the Netherlands Heart Foundation|February 20, 2015
Coronary risk factors and metabolic disorders in first-degree relatives of normocholesterolaemic patients with premature atherosclerosisC A Geluk, C J M Halkes, P P Th De Jaegere, et al.Leukemia Research|April 29, 2016
Effectivity of a strategy in elderly AML patients to reach allogeneic stem cell transplantation using intensive chemotherapy: Long-term survival is dependent on complete remission after first induction therapyP A von dem Borne, L C de Wreede, C J M Halkes, et al.Atherosclerosis|December 4, 2003
Normalization of daytime triglyceridemia by simvastatin in fasting normotriglyceridemic patients with premature coronary sclerosisJ P H van Wijk, C J M Halkes, P P Th De Jaegere, et al.Arteriosclerosis, Thrombosis, and Vascular Biology|August 23, 2003
Gender differences in postprandial ketone bodies in normolipidemic subjects and in untreated patients with familial combined hyperlipidemiaC J M Halkes, H van Dijk, C Verseyden, et al.Annals of Hematology|April 1, 2014
Clofarabine in combination with a standard remission induction regimen (cytosine arabinoside and idarubicin) in patients with previously untreated intermediate and bad-risk acute myelogenous leukemia (AML) or high-risk myelodysplastic syndrome (HR-MDS): phase I results of an ongoing phase I/II study of the leukemia groups of EORTC and GIMEMA (EORTC GIMEMA 06061/AML-14A trial)R Willemze, S Suciu, P Muus, et al.Bone Marrow Transplantation|October 3, 2017
Donor T-cell responses and disease progression patterns of multiple myelomaM Eefting, L C de Wreede, P A Von dem Borne, et al.Pageof 2